Skip Navigation
Print Page

Staff Detail

Skip sharing on social media links
Share this:

Mofenson, Lynne Meryl

Formal Title:






Silver Spring ,MD 20905


Lynne M. Mofenson, M.D., is an infectious disease specialist and board-certified pediatrician who joined the MPIDB in 1989, when it was the Pediatric and Maternal AIDS Branch, and retired from the Branch in 2014. She received her M.D. from Albert Einstein College of Medicine with honors (Alpha Omega Alpha). Dr. Mofenson served as Branch Chief, responsible for overall program planning and the development and scientific direction of research studies and clinical trials in domestic and international pediatric, adolescent, and maternal HIV infection, disease, and AIDS, for many years until her retirement in 2014. She was also project officer for the NICHD-funded multi-site Domestic and International Pediatric/Perinatal HIV Clinical Studies Network, which conducts clinical trials in treatment and management of HIV infection in infants, children, adolescents, and women both domestically and internationally, often in collaboration with other Networks, such as the Pediatric AIDS Clinical Trials Group funded by the NIAID, the Adolescent Trials Network and the Pediatric European Network for Treatment of AIDS. She served as Executive Secretary for the U.S. Public Health Service guidelines for treatment of HIV-infected children, treatment of HIV-infected pregnant women and prevention of mother to child HIV transmission, and provided consultation to the World Health Organization on treatment guidelines in resource-limited countries.


Featured Items:

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at (PDF - 1.51. MB). 

Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at (PDF - 2.69 MB).

Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58 (No. RR-11) September 4, 2009


Publications (PubMed):

Title Authors Publication Date
Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis.Nachega JB,Uthman OA,Anderson J,Peltzer K,Wampold S,Cotton MF,Mills EJ,Ho YS,Stringer JS,McIntyre JA,Mofenson LMAIDS2012 Oct 23
Unresolved antiretroviral treatment management issues in HIV-infected children.Heidari S,Mofenson LM,Hobbs CV,Cotton MF,Marlink R,Katabira EJ Acquir Immune Defic Syndr2012 Feb 1
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.Violari A,Lindsey JC,Hughes MD,Mujuru HA,Barlow-Mosha L,Kamthunzi P,Chi BH,Cotton MF,Moultrie H,Khadse S,Schimana W,Bobat R,Purdue L,Eshleman SH,Abrams EJ,Millar L,Petzold E,Mofenson LM,Jean-Philippe P,Palumbo PN Engl J Med2012 Jun 21
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.Nielsen-Saines K,Watts DH,Veloso VG,Bryson YJ,Joao EC,Pilotto JH,Gray G,Theron G,Santos B,Fonseca R,Kreitchmann R,Pinto J,Mussi-Pinhata MM,Ceriotto M,Machado D,Bethel J,Morgado MG,Dickover R,Camarca M,Mirochnick M,Siberry G,Grinsztejn B,Moreira RI,Bastos FI,Xu J,Moye J,Mofenson LM,NICHD HPTN 040/PACTG 1043 Protocol TeamN Engl J Med2012 Jun 21
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.Coovadia HM,Brown ER,Fowler MG,Chipato T,Moodley D,Manji K,Musoke P,Stranix-Chibanda L,Chetty V,Fawzi W,Nakabiito C,Msweli L,Kisenge R,Guay L,Mwatha A,Lynn DJ,Eshleman SH,Richardson P,George K,Andrew P,Mofenson LM,Zwerski S,Maldonado Y,HPTN 046 protocol teamLancet2012 Jan 21
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.Siberry GK,Williams PL,Mendez H,Seage GR 3rd,Jacobson DL,Hazra R,Rich KC,Griner R,Tassiopoulos K,Kacanek D,Mofenson LM,Miller T,DiMeglio LA,Watts DH,Pediatric HIV/AIDS Cohort Study (PHACS)AIDS2012 Jun 1
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.Ford N,Calmy A,Mofenson LAIDS2011 Nov 28
Prevention of mother-to-child HIV-1 transmission--why we still need a preventive HIV immunization strategy.Mofenson LMJ Acquir Immune Defic Syndr2011 Dec 1
Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.Heidari S,Mofenson L,Cotton MF,Marlink R,Cahn P,Katabira EJ Acquir Immune Defic Syndr2011 Aug 1
Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection.Mofenson LMClin Infect Dis2010 May 15
Protecting the next generation--eliminating perinatal HIV-1 infection.Mofenson LMN Engl J Med2010 Jun 17
Antiretroviral drugs to prevent breastfeeding HIV transmission.Mofenson LMAntivir Ther2010
Antiretroviral treatment for children with peripartum nevirapine exposure.Palumbo P,Lindsey JC,Hughes MD,Cotton MF,Bobat R,Meyers T,Bwakura-Dangarembizi M,Chi BH,Musoke P,Kamthunzi P,Schimana W,Purdue L,Eshleman SH,Abrams EJ,Millar L,Petzold E,Mofenson LM,Jean-Philippe P,Violari AN Engl J Med2010 Oct 14
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.PENPACT-1 (PENTA 9/PACTG 390) Study Team,Babiker A,Castro nee Green H,Compagnucci A,Fiscus S,Giaquinto C,Gibb DM,Harper L,Harrison L,Hughes M,McKinney R,Melvin A,Mofenson L,Saidi Y,Smith ME,Tudor-Williams G,Walker ASLancet Infect Dis2011 Apr
The challenges of success: adolescents with perinatal HIV infection.Mofenson LM,Cotton MFJ Int AIDS Soc2013 Jun 18
Cognitive Function and Neurodevelopmental Outcomes in HIV-Infected Children Older than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study.Puthanakit T,Ananworanich J,Vonthanak S,Kosalaraksa P,Hansudewechakul R,van der Lugt J,Kerr SJ,Kanjanavanit S,Ngampiyaskul C,Wongsawat J,Luesomboon W,Vibol U,Pruksakaew K,Suwarnlerk T,Apornpong T,Ratanadilok K,Paul R,Mofenson LM,Fox L,Valcour V,Brouwers P,Ruxrungtham KPediatr Infect Dis J2013 Jan 2
Tenofovir Treatment Duration Predicts Proteinuria in a Multi-Ethnic United States Cohort of Children and Adolescents with Perinatal HIV-1 Infection.Purswani M,Patel K,Kopp JB,Seage GR 3rd,Chernoff MC,Hazra R,Siberry GK,Mofenson LM,Scott GB,Van Dyke RB,for the Pediatric HIVAIDS Cohort StudyPediatr Infect Dis J2012 Dec 17
Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.Fogel JM,Mwatha A,Richardson P,Brown ER,Chipato T,Alexandre M,Moodley D,Elbireer A,Mirochnick M,George K,Mofenson LM,Zwerski S,Coovadia HM,Eshleman SHPediatr Infect Dis J2013 Apr
Combination antiretroviral use and preterm birth.Watts DH,Williams PL,Kacanek D,Griner R,Rich K,Hazra R,Mofenson LM,Mendez HA,Pediatric HIV/AIDS Cohort StudyJ Infect Dis2013 Feb 15
Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.Leroy V,Malateste K,Rabie H,Lumbiganon P,Ayaya S,Dicko F,Davies MA,Kariminia A,Wools-Kaloustian K,Aka E,Phiri S,Aurpibul L,Yiannoutsos C,Signaté-Sy H,Mofenson L,Dabis F,International IeDEA Pediatric Working Group1J Acquir Immune Defic Syndr2013 Feb 1
Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models.Rollins N,Mahy M,Becquet R,Kuhn L,Creek T,Mofenson LSex Transm Infect2012 Dec
Antiretrovirals in pregnancy: a note of caution.Watts DH,Mofenson LMJ Infect Dis2012 Dec 1
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.Puthanakit T,Saphonn V,Ananworanich J,Kosalaraksa P,Hansudewechakul R,Vibol U,Kerr SJ,Kanjanavanit S,Ngampiyaskul C,Wongsawat J,Luesomboon W,Ngo-Giang-Huong N,Chettra K,Cheunyam T,Suwarnlerk T,Ubolyam S,Shearer WT,Paul R,Mofenson LM,Fox L,Law MG,Cooper DA,Phanuphak P,Vun MC,Ruxrungtham K,PREDICT Study GroupLancet Infect Dis2012 Dec
Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief.Chi BH,Adler MR,Bolu O,Mbori-Ngacha D,Ekouevi DK,Gieselman A,Chipato T,Luo C,Phelps BR,McClure C,Mofenson LM,Stringer JSJ Acquir Immune Defic Syndr2012 Aug 15
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology